Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.46 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 3/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30025571 | 1.00 | GSK3B (0.53) | GSK3BKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL6559766 | 0.86 | KCNQ3 (0.47) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL30467135 | 0.86 | KCNQ3 (0.47) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL3502522 | 0.85 | KCNQ3 (0.46) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL7144096 | 0.85 | GSK3B (0.59) | GSK3BKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL247898 | 0.84 | CES2 (0.59) | GSK3BKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL29464070 | 0.84 | CES2 (0.59) | GSK3BKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL18538090 | 0.83 | MAPT (0.54) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL3973133 | 0.83 | GSK3B (0.55) | GSK3BKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL29499477 | 0.83 | GSK3B (0.55) | GSK3BKCNQ3KCNQ2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271509-A | Quaternary ammonium salt polyion liquid catalyst with metal chloride as anion and preparation and application thereof | 南京工业大学 | 2024-07-02 | — | — | CN | claimed |
| CN-118204038-A | Equipment for producing m-fluorobenzoic acid by dechlorination of 2, 4-dichloro-5-fluoroacetophenone | 浙江吉泰新材料股份有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-118204039-A | Displacement device for producing m-fluorobenzoic acid by dechlorination of 2, 4-dichloro-5-fluoroacetophenone | 浙江吉泰新材料股份有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117736083-A | Method for preparing 2, 4-dichloro-5-fluorobenzoic acid and 2, 6-dichloro-3-fluorobenzoic acid by taking 2, 4-dichloro-5-fluoroacetophenone crystallization mother liquor as raw material | 浙江工业大学 | 2024-03-22 | — | — | CN | claimed |
| CN-117486674-A | Comprehensive utilization method of 2, 4-dichloro-5-fluoroacetophenone crystallization mother liquor | 浙江工业大学 | 2024-02-02 | — | — | CN | claimed |
| CN-117402055-A | Resource utilization method of 2, 4-dichloro-5-fluoroacetophenone mother liquor | 浙江吉泰新材料股份有限公司 | 2024-01-16 | — | — | CN | claimed |
| CN-116514641-B | Preparation method of ciprofloxacin key intermediate | 山东国邦药业有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-116693375-B | Synthesis method of 2, 4-dichloro-5-fluoro acetophenone | 山东国邦药业有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-116554012-B | Synthetic method for preparing 2, 4-dichloro-5-fluoro acetophenone by using polysubstituted impurities | 山东国邦药业有限公司 | 2023-09-22 | — | — | CN | claimed |
| CN-116693375-A | Synthesis method of 2, 4-dichloro-5-fluoro acetophenone | 山东国邦药业有限公司 | 2023-09-05 | — | — | CN | claimed |
| WO-2010058421-A2 | A PROCESS FOR SYNTHESIS OF 2, 4-DICHLORO-5- FLUOROACETOPHENONE (DCFA) | ADITYA BIRLA SCIENCE & TECHNOLOGY CO. LTD. (IN) | 2010-05-27 | — | — | WO | claimed |
| US-20040073030-A1 | Process for the preparation of quinolone derivatives | NATCO PHARMA LIMITED (IN) | 2004-04-15 | — | — | US | claimed |
| EP-1282603-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF QUINOLONE DERIVATIVES | Natco Pharma Limited (IN) | 2003-02-12 | — | — | EP | claimed |
| WO-2001085692-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF QUINOLONE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2001-11-15 | — | — | WO | claimed |
| EP-0355774-B1 | Nucleus-fluorinated aromatic carboxylates and processes for their production | ASAHI GLASS CO LTD (JP) | 1995-04-26 | — | — | EP | claimed |
| US-4985588-A | Nucleus-fluorinated aromatic carboxylates and processes for their production | ASAHI GLASS COMPANY LTD. (JP) | 1991-01-15 | — | — | US | claimed |
| EP-0355774-A2 | Nucleus-fluorinated aromatic carboxylates and processes for their production | ASAHI GLASS COMPANY LTD. (JP) | 1990-02-28 | — | — | EP | claimed |
| EP-0131839-B1 | QUINOLINE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 1989-02-01 | — | — | EP | claimed |
| EP-0176026-B1 | PROCESS FOR THE PREPARATION OF 2,4-DICHLORO-5-FLUORO-BENZOIC ACID | BAYER AG (DE) | 1987-11-25 | — | — | EP | claimed |
| EP-0176026-A1 | Process for the preparation of 2,4-dichloro-5-fluoro-benzoic acid | BAYER AG (DE) | 1986-04-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073030-A1 | Process for the preparation of quinolone derivatives | CBR1, CYP4X1, NRAS | GSK3B 4685/4885KCNQ3 603/4885KCNQ2 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.